60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing new therapies for preventing and treating infectious diseases using biological science and applied research. The company has achieved regulatory approval for Arakoda, a malaria preventative treatment, which has been available on the market since late 2019. 60 Degrees Pharmaceuticals' development pipeline includes programs for vector-borne, fungal, and viral diseases. These programs utilize three categories of future products: new products containing the Arakoda regimen of Tafenoquine, new products containing Tafenoquine, and Celgosivir and/or botanical extracts from Australian Chestnut Trees. 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022, following the merger of 60 Degrees Pharmaceuticals, LLC into 60 Degrees Pharmaceuticals, Inc. Each outstanding membership interest in 60P LLC was converted into common stock of 60 Degrees Pharmaceuticals, Inc., with a par value of $0.0001 per share and a cost-basis of $1,200.00 per share. The company operates one majority-owned subsidiary, 60P Australia Pty Ltd, based in Sydney, Australia, in which it holds 97% equity. 60P Australia holds sub-licensing rights for several territories outside the U.S. for the company's product. 60P Australia previously solely owned 60P Singapore Pte. Ltd., a Singaporean subsidiary company, which dissolved in the second quarter of 2022. On December 17, 2025, the Board approved a 1-for-4 reverse stock split.